Table 1.
Methylation-Related Biomarkers in HCC
| Biomarker Gene | Methylation Type | Impacts and Mechanisms in HCC |
|---|---|---|
| RDH16 | DNA methyltransferase inhibitor | HCC migration11 |
| DLC1 | DNA hypomethylation | Associated with satellite lesions and incomplete tumor capsule12 |
| BAIAP2L2 | DNA methylation | Potential prognosis and therapeutic target19 |
| UBE2 | DNA methylation | Diagnostic and prognostic20 |
| RPS24 | DNA methylation | Cell proliferation and immunosuppression20 |
| STAP1 | DNA methylation | Diagnostic and prognostic value of HBV-related hepatocellular carcinoma13 |
| CCDC50 | DNA hypomethylation | HCC prognosis20 |
| CKS2 | DNA abnormal methylation | Positive correlation with immunological markers15 |
| FARSB | DNA hypomethylation | Immune infiltration16 |
| m-SEPT9 | DNA | Molecular targeted agents treatment efficacy21 |
| WHSC1 | DNA | Prognosis and therapeutic target22 |
| TET1 | Demethylation | Immune infiltration and carcinogenesis23 |
| AC115619 | M6A | Regulation of tumour progression and prognosis24 |
| KAA1429 | M6A | Sorafenib-resistant hepatocellular carcinoma and HCC tumour metastasis25 |
| AURKA | lncRNAs M6A | Prognosis and treatment26 |
| GBAP1 | M6A | Prognosis indicator and therapeutic target27 |
| LncRNA FAM111A-DT | M6A | Proliferation of HCC cells28 |
| LncRNA LEAWBIH | M6A | Therapeutic target28 |
| LncRNA H19 | M5C | Diagnosis and treatment29 |
| PRMT3 | Histone methylation | Drug resistance30 |